Trial Profile

Phase 1 trial of QT 019B in multiple autoimmune diseases

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QT 019B (Primary)
Indications Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura; Multiple sclerosis; Neuromyelitis optica; Systemic lupus erythematosus
Focus Adverse reactions; Therapeutic Use

23 Dec 2025 New trial record
08 Dec 2025 According to a Qihan Biotech media release, data from this trial was presented an oral and several poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting.
08 Dec 2025 According to a Qihan Biotech media release, companys QT-019B program is supported by IND clearance for rSLE from both the US FDA and the China NMPA. The FDA has also granted Fast Track Designation for the SLE-ITP indication. Phase 1 enrollment is actively underway.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com